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Genetic insights into the causes and classiﬁ cation of the 
cerebral palsies
Andres Moreno-De-Luca, David H Ledbetter, Christa L Martin
Cerebral palsy—the most common physical disability of childhood—is a clinical diagnosis encompassing a 
heterogeneous group of neurodevelopmental disorders that cause impairments of movement and posture that persist 
throughout life. Despite being commonly attributed to a range of environmental factors, particularly birth asphyxia, 
the speciﬁ c cause of cerebral palsy remains unknown in most individuals. A growing body of evidence suggests that 
cerebral palsy is probably caused by multiple genetic factors, similar to other neurodevelopmental disorders such as 
autism and intellectual disability. Recent advances in next-generation sequencing technologies have made possible 
rapid and cost-eﬀ ective sequencing of the entire human genome. Novel cerebral palsy genes will probably be identiﬁ ed 
as more researchers and clinicians use this approach to study individuals with undiagnosed neurological disorders. 
As our knowledge of the underlying patho physiological mechanisms of cerebral palsy increases, so will the possibility 
of developing genomically guided therapeutic interventions.
Introduction
The ﬁ rst description of cerebral palsy as a clinical entity 
is attributed to William John Little, an eminent British 
orthopaedic surgeon. In 1861, he wrote a monograph in 
which he proposed for the ﬁ rst time an association 
between perinatal asphyxia and poor neurological 
outcomes later in life.1 Three decades later, Sigmund 
Freud, a neurologist and founder of psychoanalysis, 
questioned Little’s conclusions on the cause of cerebral 
palsy. On the basis of the observation that children with 
cerebral palsy had medical comorbidities, including 
intellectual disability, epilepsy, and visual disturbances, 
he proposed that cerebral palsy could begin earlier in life, 
during in-utero brain development.2 Despite Freud’s 
hypothesis, the notion that complications during labour 
and delivery are the leading cause of cerebral palsy was 
widely accepted by the medical, scientiﬁ c, and lay 
communities. Not until almost one century later did 
large population-based studies show that only a minority 
of cerebral palsy cases result from birth asphyxia, thus 
providing support for Freud’s hypothesis.3–6
Cerebral palsy is a clinical descriptive term applied to a 
heterogeneous group of neurodevelopmental disorders 
in which motor impairments often co-occur with a range 
of medical disorders. In 2004, the International Working 
Group on the Deﬁ nition and Classiﬁ cation of Cerebral 
Palsy7 deﬁ ned cerebral palsy as “a group of permanent 
disorders of the development of movement and posture, 
causing activity limitation, that are attributed to non-
progressive disturbances that occurred in the developing 
fetal or infant brain. The motor disorders of cerebral 
palsy are often accompanied by disturbances of 
sensation, perception, cognition, communication, and 
behaviour; by epilepsy, and by secondary musculoskeletal 
problems”. Unfortunately, in some cases, once a child is 
given a clinical diagnosis of cerebral palsy, limited 
eﬀ orts, if any, are made to determine the underlying 
cause. However, identiﬁ cation of speciﬁ c causes of the 
disorder would provide individuals with cerebral palsy 
and their families with numerous beneﬁ ts, including a 
better understanding of the disorder, accurate assessment 
of recurrence risk, and early intervention; it would also 
encourage further research into the development of 
speciﬁ c medical treatments and therapeutic interventions 
for cerebral palsy.
Here, we review the growing body of evidence sup-
porting the contribution of genetic abnormalities to 
cerebral palsy. We discuss previously proposed environ-
mental risk factors and their eﬀ ects on obstetric 
management and medical malpractice litigation. We also 
present an overview of the rapidly changing ﬁ eld of 
cerebral palsy genetics, from the initial targeted association 
studies, which had inconclusive results, to the successful 
implementation of genome-wide, exon-level, copy-number 
array analyses and whole-exome sequencing that have 
enabled discovery of novel cerebral palsy genes and 
syndromes. Finally, we provide our perspective on present 
diagnostic challenges and directions for future research.
Epidemiology and classiﬁ cation
Cerebral palsy is the most common cause of physical 
disability in childhood.8 The worldwide prevalence of 
cerebral palsy has remained stable at 2–3 per 
1000 livebirths for more than four decades,9 despite 
substantial improvements in obstetric and neonatal care. 
A recent report from the Centers for Disease Control and 
Prevention8 noted a prevalence of 3·3 per 1000 8-year-old 
children from four areas of the USA. Moreover, up to an 
estimated 1 million children and adults in the USA 
live with a diagnosis of cerebral palsy, with an average 
lifetime cost per aﬀ ected individual in 2003 of 
US$921 000.10,11 Because of the increasing life expectancy 
of individuals with cerebral palsy, the number of adults 
with this disorder is increasing and their medical and 
social care needs are changing.10
Cerebral palsy can be classiﬁ ed on the basis of four 
major components: type and severity of the motor 
abnormalities, anatomical distribution, associated 
impairments, and timing of the presumed causal event 
(prenatal, perinatal, or postnatal).12 A thorough physical 
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and neurological examination can help to identify 
abnormal neuromuscular tone (hypotonia or hypertonia) 
and the predominant type of motor impairment, which 
can be spastic, ataxic, dyskinetic (dystonia or 
choreoathetosis), or mixed. The characteristics and 
severity of the motor impairments should be described 
for each limb and the trunk to diﬀ erentiate unilateral 
from bilateral involvement and to establish an anatomical 
distribution (monoplegia, diplegia, triplegia, hemiplegia, 
and tetraplegia).13 These classiﬁ cation systems, which are 
based on motor type and topography, are often used to 
infer which area of the brain might be aﬀ ected (pyramidal 
or extrapyramidal systems); however, they have poor 
reliability, even among experienced clinicians.14,15
In an eﬀ ort to establish an accurate, reliable, and 
standardised system to classify cerebral palsy, Palisano 
and colleagues16 developed the gross motor function 
classiﬁ cation system (GMFCS), a ﬁ ve-level classiﬁ cation 
based on the child’s gross motor abilities, functional 
limitations, and need for wheeled mobility or assistive 
devices.16 The GMFCS has been successfully implemented 
worldwide in a range of settings including routine clinical 
management (mobility assessment, intervention 
planning, and prognosis), research (sample selection and 
stratiﬁ cation), and health-care admin istration.17–19 A 
similar scale to assess bimanual ﬁ ne motor function has 
been developed and validated as a complement to the 
GMFCS,20,21 and a manual ability classiﬁ cation system 
has been designed to assess the ability of children with 
cerebral palsy to use their hands for routine activities.22 
Furthermore, the communication function classiﬁ cation 
system was recently developed in an eﬀ ort to assess the 
functional communication competence of individuals 
with cerebral palsy in daily life situations.23 The 
development of objective and valid functional 
classiﬁ cation systems has greatly improved health-care 
delivery and standardised research eﬀ orts.16,18 
Although the hallmark feature of cerebral palsy is 
motor and posture deﬁ cit, patients often present with 
several other impairments and medical disorders. 
Commonly reported comorbidities include intellectual 
disabilities in 30–65%, seizure disorders in 30–50%, 
speech and language deﬁ cits in 40%, visual impairments 
in 40%, and hearing problems in 5–15% of patients.24–28 
Additional systems that might be aﬀ ected include 
the somatosensory (deﬁ cits in stereognosis and 
proprioception),29 genitourinary (enuresis, urinary 
infections, and voiding dysfunction),30,31 gastrointestinal 
(dysphagia, gastroesophageal reﬂ ux disease, and 
constipation),32 respiratory (recurrent pneumonia, 
atelectasis, bronchiectasis, and restrictive lung disease),32 
and endocrine systems (reduced growth and 
osteopenia).33,34 Furthermore, 20% of individuals with 
cerebral palsy have psychosocial and behavioural 
problems and 9% have an autism spectrum disorder.35 
The severity of the motor impairment, along with the 
presence and extent of accompanying disorders, 
inﬂ uences the functional ability of individuals with 
cerebral palsy and also aﬀ ects the burden and challenges 
faced by caregivers and the health system.
Causes
The causes of cerebral palsy have been attributed to a 
wide range of prenatal, perinatal, and postnatal factors 
that can present as single, isolated factors or as a 
combination of multiple potential risk factors. The 
presence and contribution of individual events varies to 
some extent between gestational groups and cerebral 
palsy subtypes.36 The most commonly reported risk 
factors include prematurity, low birthweight, birth 
asphyxia, fetal intrauterine exposure to maternal infection 
and inﬂ ammation, maternal fever during labour, multiple 
gestations, coagulation disorders and ischaemic stroke in 
the fetus or newborn, maternal thyroid disease, and 
placental pathology.37–39 However, despite the large 
number of known and proposed causes, the speciﬁ c 
causal mechanism remains elusive in most cases of 
cerebral palsy.
Perhaps the most studied, and still controversial, risk 
factor associated with cerebral palsy is birth asphyxia. 
Historically, and unfortunately still today in many groups 
(eg, researchers, clinicians, and the general public), 
inadequate oxygen delivery to the brain, caused by adverse 
intrapartum events, is assumed to be the leading cause of 
cerebral palsy.40–42 On the basis of this hypothesis, detection 
and early intervention in episodes of acute birth asphyxia 
were proposed as ways to decrease the rate of cerebral 
palsy and improve long-term neurological outcomes of 
newborns at risk.43,44 To that extent, technologies such as 
electronic fetal monitoring during birth were developed 
and rapidly introduced into clinical practice, without 
adequate supporting evidence from scientiﬁ c studies.43,44 
Electronic fetal monitoring, considered a standard of care 
by many physicians and institutions, is now widely used 
to detect early fetal distress resulting from hypoxia during 
delivery, and despite a ﬁ ve-times increase in the rate of 
caesarean sections, driven partly by the use of electronic 
fetal monitoring,8 the incidence of cerebral palsy has not 
decreased over time.9,45,46 Moreover, large population-based, 
controlled studies, done in various countries, over diﬀ erent 
timeframes, and across diﬀ erent populations, have shown 
that birth asphyxia is an uncommon cause of neonatal 
encephalopathy and accounts for less than 10% of cerebral 
palsy cases.3,5,47–50
Even though most cases of cerebral palsy are not caused 
by birth asphyxia and those that are can rarely be 
prevented by obstetric intervention,51 between 1999 and 
2003 an estimated 76% of obstetricians in the USA faced 
medical malpractice litigation, most often for alleged 
birth mismanagement resulting in cerebral palsy.44 A 
similar situation was reported in a 2002 study from 
Australia, which reported that 18% of the total medical 
indemnity claims were attributed to the 2% of physicians 
who practise obstetrics.52
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In an eﬀ ort to help clinicians, researchers, and law 
courts to identify whether an acute intrapartum event 
was probably the cause of any particular case of cerebral 
palsy, an objective template of evidence was published by 
the International Cerebral Palsy Task Force.53 These 
guidelines, which are endorsed by multiple medical 
colleges and societies worldwide, provide three essential 
and ﬁ ve non-essential criteria to deﬁ ne an acute 
intrapartum hypoxic event (panel). The absence of any of 
the essential criteria strongly suggests that intrapartum 
hypoxia was not the cause of cerebral palsy.
An alternative hypothesis is that cerebral palsy is caused 
by many diverse and individually rare genomic 
abnormalities, as with other developmental brain 
disorders such as intellectual disabilities,54 autism 
spectrum disorders,55 and epilepsy.56 However, as opposed 
to other neurodevelopmental disabilities, the contribution 
of genomic abnormalities to the occurrence of cerebral 
palsy has not been researched extensively, although in 
the authors’ opinion it probably accounts for a substantial 
proportion of the 70–80% of cases that are attributed to 
prenatal causes. Furthermore, genomic abnormalities 
could also be the underlying cause in cases in which 
classic risk factors such as prematurity, coagulopathies, 
or diﬃ  cult birth are identiﬁ ed.57 Children with 
malformations of cortical development present with birth 
complications more frequently than those without these 
malformations, which often results in the misdiagnosis 
of intrapartum asphyxia.58
Evidence for genetic factors in cerebral palsy
Several lines of evidence support the theory that multiple 
genetic factors contribute to the cause of cerebral palsy. 
First, mutations in multiple genes result in mendelian 
disorders that present with cerebral palsy-like features 
(as discussed below), and several single-gene mutations 
have been identiﬁ ed in idiopathic (ie, non-syndromic) 
cerebral palsy pedigrees.59–63 Second, the prevalence of 
congenital anomalies in individuals with cerebral palsy 
(11–32%) is signiﬁ cantly higher than in the general 
population (2–3%).64,65 Most malformations in children 
with cerebral palsy are cerebral (72%), of which 
microcephaly (26%) and hydrocephaly (19%) are the most 
common.64 Among the non-cerebral malformations, the 
most frequent are cardiac (29%), musculo skeletal (14%), 
and urinary abnormalities (9%), and facial clefts 
(18%).64,66,67 Third, register-based studies have reported a 
signiﬁ cantly higher concordance rate for cerebral palsy 
in monozygotic twins than in dizygotic twin pairs 
(p=0·0026).68 Fourth, the risk of cerebral palsy in 
consanguineous families is about 2·5 times higher than 
the risk in outbred families.69,70 Fifth, several studies have 
reported familial aggregation of cerebral palsy, including 
identical cerebral palsy syndromes in the same family.71–75 
Sixth, a paternal age eﬀ ect has been described in some 
forms of cerebral palsy.76 Furthermore, a quantitative 
analysis of risk factors in 681 individuals with congenital 
cerebral palsy, from the west Swedish population-based 
cerebral palsy study, estimated that 60% of hemiplegic 
cerebral palsy cases, 45% of spastic diplegic cases, and an 
estimated 100% of cases with isolated ataxia, were caused 
by genetic mutations.77 The mathematical method used 
for this study, which was based on medical history 
analysis of prenatal and perinatal risk factors, has been 
previously validated and successfully applied for the 
study of individuals with intellectual disabilities.78
Despite the growing body of evidence for genomic 
causes of cerebral palsy, it has traditionally been proposed 
that genetic and metabolic abnormalities should be 
ruled out before a diagnosis of cerebral palsy is made.79 
However, comprehensive genetic testing is rarely, if ever, 
oﬀ ered as part of the diagnostic workup of individuals 
with suspected cerebral palsy, which makes cerebral palsy 
gene discovery a challenging task. Furthermore, in 
several studies in which individuals with cerebral palsy 
were found to harbour genetic mutations, the diagnosis 
was often changed and cerebral palsy was regarded as an 
initial misdiagnosis.80 At present, our knowledge of the 
genomic component of cerebral palsy lags behind that of 
other neurodevelopmental disorders, such as intellectual 
disabilities and autism spectrum disorders.
The cerebral palsy spectrum disorders
Cerebral palsy is a non-speciﬁ c clinical diagnosis made 
on the basis of the presence of signs and symptoms, 
such as delayed motor development and abnormalities 
in posture, muscle tone, coordination, and reﬂ exes. 
Thus, it is not uncommon for individuals with a wide 
range of neurodevelopmental conditions to be 
Panel: Criteria proposed by the International Cerebral Palsy 
Task Force to deﬁ ne an acute intrapartum hypoxic event
Essential criteria
1 Evidence of a metabolic acidosis in intrapartum fetal, 
umbilical arterial cord, or very early neonatal blood 
samples (pH <7·00 and base deﬁ cit ≥12 mmol/L)
2 Early onset of severe or moderate neonatal 
encephalopathy in infants of ≥34 weeks’ gestation
3 Cerebral palsy of the spastic quadriplegic or 
dyskinetic type
Criteria that together suggest an intrapartum timing but 
by themselves are non speciﬁ c
4 A sentinel (signal) hypoxic event occurring immediately 
before or during labour
5 A sudden, rapid, and sustained deterioration of the fetal 
heart rate pattern, usually after the hypoxic sentinel 
event, where the pattern was previously normal
6 Apgar scores of 0–6 for longer than 5 min
7 Early evidence of multisystem involvement
8 Early imaging evidence of acute cerebral abnormality
Reproduced from MacLennan,53 by permission of the BMJ Publishing Group.
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diagnosed with cerebral palsy.81 Several single-gene 
(mendelian) disorders, inherited as autosomal 
dominant, autosomal recessive, or X-linked, often 
present with clinical features similar to cerebral palsy 
(webappendix). In such cases, individuals might live 
with a diagnosis of cerebral palsy for several years 
before speciﬁ c molecular or biochemical diagnostic 
testing is done. Some of these mendelian disorders are 
individually rare, but as a group they are not uncommon 
and should all be considered when assessing an 
individual with cerebral palsy. Moreover, the spectrum 
of cerebral palsy-like syndromes includes some genetic 
conditions that, once identiﬁ ed, can be successfully 
treated with available drugs.
Of particular interest, because of the potential for 
genomically guided therapeutic interventions, is the 
group of dopa-responsive dystonic disorders caused by 
mutations in the GCH1 (GTP cyclohydrolase 1), SPR 
(sepiapterin reductase), and TH (tyrosine hydroxylase) 
genes.82 If untreated, individuals with these disorders can 
progress to a state of complete loss of ambulation, 
whereas appropriate management with levodopa results 
in a dramatic and sustained improvement in symptoms, 
even in advanced cases.83
Recently, Lee and colleagues84 reported the case of a 
severely disabled young woman who presented with 
bilateral club foot, stiﬀ ness of the trunk, neck, and arms, 
and an inability to walk. She had lived with a diagnosis of 
cerebral palsy for more than 10 years until a small dose of 
levodopa was prescribed and dramatically improved her 
condition, prompting further genetic testing. Sequencing 
of the GCH1 gene identiﬁ ed a pathogenic mutation and a 
diagnosis of dopa-responsive dystonia was made. Because 
of shared clinical features, up to 24% of patients with 
dopa-responsive dystonia are initially diagnosed with 
cerebral palsy.85 Furthermore, a recent report by 
Bainbridge and colleagues86 described a twin pair with 
dopa-responsive dystonia of unknown cause (previously 
diagnosed as cerebral palsy), whose genomes were 
sequenced and found to contain compound heterozygous 
mutations in the SPR gene. Because disruption of this 
gene leads to a decrease in tetrahydrobiopterin (cofactor 
for the synthesis of dopamine and serotonin), their 
management with levodopa was supplemented with a 
serotonin precursor (oxitriptan), which resulted in 
symptomatic improvement after 1 week of treatment. 
These examples show the importance of undertaking 
comprehensive genetic testing in individuals with 
disorders of the cerebral palsy spectrum, and provide 
compelling evidence for genomically oriented medical 
decision making.
Another group of genomic diseases that often presents 
as cerebral palsy is the hereditary spastic paraplegias 
(HSP). These disorders are characterised by leg weakness 
and spasticity arising from length-dependent, distal 
axonopathy of the corticospinal tract ﬁ bres.87 More than 
40 loci have been mapped for HSP, which can be 
inherited in an autosomal dominant, autosomal recessive, 
or X-linked fashion.88 Rainier and colleagues89 assessed a 
34-year-old woman who had been diagnosed with spastic 
diplegic cerebral palsy in early childhood. When her 
10-month-old child presented with similar symptoms, 
both mother and child were diagnosed with autosomal 
dominant, uncomplicated, early-onset HSP. Further 
genetic testing identiﬁ ed a heterozygous mutation in the 
ATL1 (atlastin GTPase 1) gene, which is responsible for 
spastic paraplegia type 3A.
The webappendix summarises additional mendelian 
disorders that present with features of cerebral palsy, 
including recognisable genetic disorders such as 
Rett (MECP2)90 and Angelman (UBE3A) syndromes;91 
metabolic disorders including Lesch-Nyhan syndrome 
(HPRT)92 and glutaric acidemia type 1 (GCDH);93 heritable 
thrombophilias, such as protein C deﬁ ciency (PROC);57 
and cerebral dysgenesis such as classic lissencephaly 
(PAFAH1B1)94 and pontocerebellar hypoplasia type 1 
(VRK1).95
Single-gene causes of idiopathic cerebral palsy
As described below, the identiﬁ cation of the ﬁ rst 
cerebral palsy genes was accomplished by positional 
cloning techniques, such as microsatellite-based linkage 
mapping, followed by conventional (Sanger) sequencing 
of candidate genes in large multi-generational families 
with multiple aﬀ ected individuals.59 More recent studies 
have relied on high-resolution copy number variation 
analyses and next-generation sequencing technologies 
for gene discovery.61–63 At the time of this Review, the total 
number of genes with mutations causing human disease 
was 2687,96 of which six are known to cause mendelian 
forms of cerebral palsy (table 1).59–63 The list of monogenic 
causes of cerebral palsy will probably grow exponentially 
because of the increasing use of cutting-edge genomic 
technologies to assess individuals with undiagnosed 
disorders of brain development.
GAD1
In 2004, Lynex and colleagues59 were the ﬁ rst group to 
identify a gene linked to a mendelian form of cerebral 
palsy. They reported two consanguineous families in 
which six individuals presented with congenital spastic 
cerebral palsy of unknown cause. All individuals had 
global developmental delay, moderate-to-severe 
intellectual disability, poor or absent speech, and 
spasticity with hypertonia and brisk reﬂ exes pre-
dominantly in the legs. One family member also had 
micro cephaly, contractures, and kyphoscoliosis, and 
another had bilaterally dislocated hips that needed 
surgical management. With 290 polymorphic DNA 
markers for linkage mapping, a 5 cM region of homo-
zygosity was identiﬁ ed on chromosome 2q24-q25 and 
subsequently reﬁ ned to 0·5 cM by microsatellite typing. 
The region included the GAD1 gene, which encodes the 
brain-expressed isoform of glutamate decarboxylase, and 
See Online for webappendix
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was considered a good candidate gene for cerebral palsy 
by Lynex and colleagues.59 Direct sequencing of GAD1 in 
aﬀ ected and unaﬀ ected individuals from both families 
revealed a homozygous missense mutation segregating 
with the cerebral palsy phenotype. Glutamate de-
carboxylase is responsible for the production of GABA, 
the major inhibitory neurotransmitter, from its excitatory 
counterpart glutamate. Both molecules, and the balance 
between excitatory and inhibitory neurotransmission, 
which is modulated partly by GAD1, are crucial for 
normal brain development and synaptic plasticity.97
KANK1
1 year after the discovery of the ﬁ rst cerebral palsy gene, 
Lerer and colleagues60 studied a large four-generation 
pedigree in which nine children had cerebral palsy. 
All aﬀ ected individuals were born after normal 
pregnancies and showed congenital hypotonia that 
evolved to spastic tetraplegia within the ﬁ rst year of life. 
Additional features included moderate-to-severe intel-
lectual disability, nystagmus, and brain atrophy with 
ventriculomegaly. Linkage analysis showed that a region 
on chromosome 9p24.3 seemed to harbour the causative 
gene. Further studies identiﬁ ed a 225 kb deletion on 
9p24.3 involving one gene, KANK1 (KN motif and ankyrin 
repeat domains 1, previously called ANKRD15), in 
aﬀ ected individuals in the family, which was not identiﬁ ed 
in 210 control individuals. KANK1 is expressed in the 
developing brain and is thought to play a part in protein–
protein interactions and adhesion complexes.60 More-
over, the KANK family of proteins regulates actin 
polymerisation and cell migration.98
The adaptor protein complex-4 deﬁ ciency syndrome: 
AP4M1, AP4E1, AP4B1, and AP4S1
In 2009, Verkerk and colleagues61 reported data from 
a consanguineous Moroccan family in which ﬁ ve sib lings 
had cerebral palsy. They presented with infantile hypotonia 
that progressed to spastic tetraplegia with hypertonia and 
hyper-reﬂ exia, severe intellectual disability, absent speech, 
and absence of independent walking and sphincter 
control. Additional features included microcephaly, 
drooling, and stereotypical laughter. Neuroimaging 
studies showed diﬀ use white matter loss, ventriculomegaly, 
and cerebellar atrophy. Post-mortem neuropathological 
examination of a patient who died of aspiration pneumonia 
at 17 months revealed reduced myelin in cerebral white 
matter compared with normal brains and abnormal 
dendritic arborisation of cerebellar Purkinje cells 
compared with an age-matched control individual. Using 
homozygosity mapping followed by candidate gene 
sequencing, a homozygous mutation in the AP4M1 gene, 
encoding the μ subunit of the adaptor protein complex-4 
(AP-4), was identiﬁ ed in all aﬀ ected individuals.
After this report, our group62 reported a Palestinian-
Jordanian inbred kindred with two siblings aﬀ ected by 
a type of cerebral palsy that resembled that of the 
indi viduals previously described.61 Both patients 
presented at birth with microcephaly and hypotonia that 
progressed to spastic tetraplegia with hyper-reﬂ exia and 
generalised hypertonia. They also had severe intellectual 
disability, generalised tonic-clonic seizures, absent 
speech, an inability to walk or to control sphincters, 
drooling, and outbursts of stereotypical laughter. 
Dysmorphic features included bitemporal narrowing, 
down-slanted palpebral ﬁ ssures, a broad nasal bridge, 
and a short philtrum. Brain MRI showed ventriculomegaly, 
cerebellar atrophy, reduced hippo campal volume, and 
white matter loss. We did copy number array analyses 
and identiﬁ ed a homozygous deletion on chromosome 
15q21.2 that included exons 1–11 of the AP4E1 (ε subunit 
of AP-4) gene in both individuals.
On the basis of ﬁ ndings from these two unrelated 
cerebral palsy pedigrees, each of which had a 
homozygous mutation in a diﬀ erent subunit of AP-4 
(AP4E162 and AP4M161), along with previous ﬁ ndings 
that mutations in a third subunit (the β subunit) result 
in axonal abnormalities in mice,99 we proposed that 
disruption of any one of the four subunits of AP-4 
(AP4E1, AP4M1, AP4B1, and AP4S1) would result in 
dysfunction of the entire complex and lead to a distinct 
autosomal recessive cerebral palsy disorder, which we 
deﬁ ned as AP-4-deﬁ ciency syndrome.62
Our hypothesis was conﬁ rmed by a recent study of eight 
individuals, from three consanguineous families, who 
presented with a similar phenotype to that described in 
the previous patients (summarised in table 2).63 In 
addition to sharing many neurodevelopmental features, 
these individuals had common dysmorphisms, including 
a wide nasal bridge, bulbous nose, and coarse features. By 
autozygosity mapping followed by either sequencing of 
candidate genes or whole-exome sequencing, mutations 
in AP4E1, AP4B1 (β subunit of AP-4), and AP4S1 ( subunit 
of AP-4) were identiﬁ ed in aﬀ ected individuals from each 
of the three pedigrees.63 Furthermore, a recent study of 
136 consanguineous families with autosomal recessive 
intellectual disability identiﬁ ed mutations in AP4E1 and 
AP4M1 in two unrelated families with ﬁ ve individuals 
aﬀ ected by severe intellectual disability, microcephaly, 
and spastic paraplegia.100
These ﬁ ndings from 20 aﬀ ected individuals from 
seven unrelated consanguineous families provide 
Name OMIM ID Inheritance Reference
GAD1 Glutamate decarboxylase 1 603513 AR Lynex et al59
KANK1 KN motif and ankyrin repeat domains 1 612900 AD Lerer et al60
AP4M1 Adaptor-related protein complex 4, μ1 subunit 612936 AR Verkerk et al61
AP4E1 Adaptor-related protein complex 4, ε1 subunit 613744 AR Moreno-De-Luca et al62
AP4B1 Adaptor-related protein complex 4, β1 subunit 614066 AR Abou Jamra et al63
AP4S1 Adaptor-related protein complex 4, σ1 subunit 614067 AR Abou Jamra et al63
OMIM=Online Mendelian Inheritance in Man. AR=autosomal recessive. AD=autosomal dominant.
Table 1: Genes associated with cerebral palsy
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compelling evidence for pathogenic mutations in each 
of the four genes encoding the AP-4 complex 
subunits.61–63,100 Furthermore, because all aﬀ ected 
individuals presented with a similar cerebral palsy 
phenotype, the existence of an AP-4-deﬁ ciency syndrome 
is conﬁ rmed, deﬁ ning a clinically and genetically 
recognisable form of cerebral palsy.
The AP-4 complex
The adaptor protein complexes AP-1, AP-2, AP-3, and 
AP-4 are ubiquitously expressed heterotetrameric 
structures that play a crucial part in vesicular traﬃ  cking 
of membrane proteins along the late secretory and 
endocytic pathways.101 They create an interface between 
cargo molecules and an outer coat protein, thus promoting 
the assembly of coated vesicles. The AP complexes are 
composed of four diﬀ erent subunits that come together 
to form a heterotetramer: one large variable subunit (γ in 
AP-1, α in AP-2, δ in AP-3, and ε in AP-4), one large 
subunit with high homology between the complexes 
(β1-4), one medium subunit (μ1-4), and one small subunit 
(1-4).102 Although all four AP complexes share a common 
structural pattern, each one targets a diﬀ erent set of cargo 
proteins to be included into coated vesicles and sorted 
along a speciﬁ c traﬃ  cking route.
The AP-4 complex is expressed in the CNS throughout 
the embryologic and postnatal developmental stages.61,103 
It selectively sorts proteins from the trans-Golgi network 
to the postsynaptic somatodendritic domain, avoiding 
the presynaptic axonal domain, thus helping to establish 
neuronal polarity.104 Known cargo molecules sorted by 
AP-4 include AMPA and δ2 glutamate receptors, 
transmembrane AMPA receptor regulatory proteins, 
low-density lipoprotein receptors, and Alzheimer’s 
disease amyloid precursor protein (APP).99,103,105 Because 
AMPA receptors participate in excitatory synaptic 
transmission, adequate AP-4-mediated traﬃ  cking of 
these receptors to their target membrane is crucial for 
neurotransmission and synaptic plasticity. Moreover, 
AP-4-dependent transport of APP reduces γ secretase 
cleavage of the precursor protein to the pathogenic 
amyloid-β peptide.105 Therefore, deﬁ ciency of AP-4 has 
the potential to disturb crucial neurophysiological 
processes, leading to increased amyloidogenic processing 
of APP and abnormal synaptic transmission due to 
deﬁ cient cycling of glutamate receptors.
In an eﬀ ort to deﬁ ne the role of AP-4 in neurons, 
Matsuda and colleagues99 disrupted the gene encoding 
the β subunit of the complex in mice, both in vitro and 
in vivo. AP-4-deﬁ cient mice showed no major brain 
anomalies but did less well on the rotorod test than wild-
type mice. Furthermore, examination of cerebellar 
Purkinje cells and hippocampal neurons revealed axonal 
swelling and accumulation of AMPA, δ2, and low-density 
lipoprotein receptors in autophagosomes near the axon 
terminals. These ﬁ ndings suggest that AP-4 deﬁ ciency 
results in loss of somatodendritic-speciﬁ c sorting of 
cargo molecules, leading to mislocalisation of such 
proteins to the axonal domain and further degradation 
via the autophagic pathway. Together, these ﬁ ndings 
highlight the crucial role of vesicular traﬃ  cking in brain 
development and function, and show how disturbances 
in diﬀ erent proteins along a shared biological pathway 
can lead to disorders with similar clinical phenotypes. 
Furthermore, these ﬁ ndings show that several genes and 
proteins involved in the AP-4-mediated vesicular 
traﬃ  cking pathway are strong candidate genes for 
cerebral palsy. Further studies are needed to establish the 
frequency of AP-4-deﬁ ciency syndrome and to explore 
the contribution of other genes in this pathway to the 
development of cerebral palsy.
Genetic association studies
On the basis of the hypotheses that abnormalities in 
the inﬂ ammatory system and the coagulation cascade 
might contribute to the causal pathway of cerebral palsy, 
numerous studies have explored whether single 
nucleotide polymorphisms (SNPs) in a subset of genes 
involved in these processes confer an increased risk for 
cerebral palsy. Some of the most studied poly morphisms 
are located within genes that code for factor V Leiden, 
prothrombin, methylenetetrahydrofolate reductase, 
apo lipoprotein E (APOE ε2 and ε4 alleles), inter-
leukins 6 and 8, nitric oxide synthase (endothelial and 
inducible), platelet activator inhibitor, endothelial 
protein C receptor, mannose binding lectin, tumour 
Frequency
Male:female ratio 1·1:1
Severe intellectual disability 15/15 (100%)
Hypotonia progressing to hypertonia 14/14 (100%)
Hyper-reﬂ exia 11/11 (100%)
Short stature 8/8 (100%)
Absent speech 13/14 (93%)
Stereotypical laughter 13/14 (93%)
Spasticity 13/14 (93%)
Inability to walk 13/14 (93%)
Babinski sign 8/9 (89%)
Microcephaly 11/14 (79%)
Absent sphincter control 11/14 (79%)
Drooling 10/14 (71%)
Foot deformity 6/13 (46%)
Overweight 2/8 (25%)
Epilepsy 3/15 (20%)
Ventriculomegaly 5/6 (83%)
Cerebellar atrophy 3/6 (50%)
Abnormal white matter 3/6 (50%)
Data are n/N (%), unless otherwise stated. Information on all the clinical features 
was not available for all 15 individuals. Data from Verkerk and colleagues,61 
Moreno-De-Luca  and colleagues,62 and Abou Jamra and colleagues.63 
Table 2: Summary of clinical ﬁ ndings in 15 individuals with 
AP-4-deﬁ ciency syndrome
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necrosis factor α, and lymphotoxin-α.106 Despite more 
than 20 case-control studies focused on these candidate 
genes, the results are inconsistent and often conﬂ icting. 
In an eﬀ ort to increase the statistical power of individual 
studies, Wu and colleagues107 undertook a meta-analysis 
exploring 17 polymorphisms in 2533 cases and 
4432 control individuals from 11 studies and concluded 
that only one SNP in interleukin-6 (rs1800795) was 
signiﬁ cantly associated with cerebral palsy.107
In 2009, O’Callaghan and colleagues108 applied the 
human genome epidemiology network (HuGENet) 
guidelines to undertake a systematic review of 
22 targeted association studies in individuals with 
cerebral palsy. Multiple polymorphisms were analysed, 
including 18 SNPs in thrombophilic genes, eight in 
cytokine genes, APOE ε2, ε3, and ε4 alleles, and 
23 polymorphisms in genes involved in other systems. 
The authors concluded that because of limited sample 
sizes, ethnically diverse cohorts, and inadequate control 
individuals in most studies, proposed associations 
of SNPs and cerebral palsy outcome remained con-
troversial.108 However, some candidate genes, including 
factor V Leiden, methylene tetrahydrofolate reductase, 
lymphotoxin-α, tumour necrosis factor-α, endothelial 
nitric oxide synthase, and mannose binding lectin, were 
more promising than the rest in O’Callaghan and 
colleagues’ opinion. The most recent population-based, 
case-control study investigating genetic poly morphisms 
in cerebral palsy included 138 cases and 165 control 
individuals from 334 333 infants born at term or near 
term in a health-care organisation in California, USA.106 
In an eﬀ ort to replicate previously proposed associations 
between genetic polymorphisms and cerebral palsy, 
15 well studied SNPs were genotyped. After correcting 
for multiple comparisons, no statistically signiﬁ cant 
association between any SNP and cerebral palsy was 
identiﬁ ed.
Genetic association studies have failed to reach 
strong, replicable results when applied to complex, 
multi factorial, and highly heterogeneous groups of 
disorders, such as cerebral palsy. The genomic makeup 
of cerebral palsy probably resembles that of other 
developmental brain disorders that result from multiple 
rare, and often private (ie, mutations rare enough to be 
restricted to an individual or kindred), genetic variations 
that are infrequently detected in association studies.55,109 
Further more, because all cerebral palsy association 
studies so far have been hypothesis driven, only a 
limited number of polymorphisms within a small group 
of candidate genes have been assessed. At present, 
commercially available genotyping platforms feature 
more than 1·5 million markers that can be used 
simultaneously for genome-wide association studies 
and copy number variation analyses. The imple men-
tation of whole-genome scans, as an unbiased approach 
to study individuals with cerebral palsy, could enable 
discovery of novel cerebral palsy genes and biological 
pathways to further unravel the genomic underpinnings 
of this disorder.
Whole-exome and genome sequencing
The longstanding quest to ﬁ nd the cause of some of the 
most common neurodevelopmental disorders, as well as 
rare conditions with suspected genetic causes, has 
recently made rapid progress, with exciting new ﬁ ndings. 
A major factor in this success comes from recent advances 
in next-generation sequencing tech nologies, which have 
allowed rapid and cost-eﬀ ective sequencing of the entire 
human genome or a subset that includes all coding genes, 
referred to as the exome.110 Exome sequencing has been 
successfully implemented to uncover the causative gene 
in a range of mendelian disorders, including MLL2 in 
Kabuki syndrome,111 DHODH in Miller syndrome,112 and 
KIF1A in hereditary spastic paraparesis.113 Furthermore, 
the widespread use of trio-based exome sequencing as the 
standard approach to study complex neurodevelopmental 
disorders has resulted in the discovery of pathogenic 
de-novo mutations in multiple genes for intellectual 
disability,114 autism spectrum disorders,115 and schizo-
phrenia.116 These ﬁ ndings support the notion that 
developmental brain disorders such as cerebral palsy are 
probably caused by hundreds of genes, and that systematic 
family-based exome or genome sequencing has the power 
to uncover them.
Conclusions
The ﬁ eld of cerebral palsy genetics is rapidly growing and 
has already changed our understanding of the 
underpinnings of this complex disorder. Multiple 
monogenic syndromes that present with cerebral palsy-
like features (cerebral palsy spectrum disorders) should be 
considered as part of the diagnostic assessment of 
individuals with suspected cerebral palsy. Furthermore, we 
now know of six genes that can cause cerebral palsy when 
disrupted, and we estimate that many other develop mental 
brain genes probably contribute to the genetic heterogeneity 
of this disorder. The availability of personal and family-
based genome sequencing has made identi ﬁ cation of rare 
or private mutations in cerebral palsy families feasible at a 
reasonable cost—at present for research and soon on a 
clinical diagnostic basis. Moreover, the continuous 
discovery of genes and molecular pathways that are 
Search strategy and selection criteria
References for this Review were identiﬁ ed through searches 
of PubMed with the search terms “neurogenetics”, “genetics”, 
“genomics”, “genes”, “mutations”, “chromosomes”, and 
“cerebral palsy” from inception to November, 2011. Articles 
were also identiﬁ ed through searches of the authors’ own 
ﬁ les. Only papers published in English were reviewed. The 
ﬁ nal reference list was generated on the basis of originality 
and relevance to the broad scope of this Review.
For HuGENet see http://www.
cdc.gov/genomics/hugenet/
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disrupted in cerebral palsy will increase the possibility of 
developing genomically guided pharma cological 
interventions for this disorder. As the paradigm shift 
continues and more researchers, clinicians, and the 
general population start to consider the cerebral palsies as 
a group of neurogenetic disorders, we will probably witness 
an increase in research eﬀ orts, a change in the diagnostic 
approach, and eventually novel therapies for cerebral palsy. 
This exciting new era of cerebral palsy genomics will 
unquestionably beneﬁ t this patient population.
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